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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive disease with poor prognostic implications. This is
partly due to a large proportion of PDACs carrying mutations in TP53, which impart gain-of-function characteristics
that promote metastasis. There is evidence that microRNAs (miRNAs) may play a role in both gain-of-function TP53
mutations and metastasis, but this has not been fully explored in PDAC. Here we set out to identify miRNAs which are
specifically dysregulated in metastatic PDAC. To achieve this, we utilised established mouse models of PDAC to profile
miRNA expression in primary tumours expressing the metastasis-inducing mutant p53R172H and compared these to
two control models carrying mutations, which promote tumour progression but do not induce metastasis. We show
that a subset of miRNAs are dysregulated in mouse PDAC tumour tissues expressing mutant p53R172H, primary cell
lines derived from mice with the same mutations and in TP53 null cells with ectopic expression of the orthologous
human mutation, p53R175H. Specifically, miR-142-3p is downregulated in all of these experimental models. We found
that DNA methyltransferase 1 (Dnmt1) is upregulated in tumour tissue and cell lines, which express p53R172H. Inhibition
or depletion of Dnmt1 restores miR-142-3p expression. Overexpression of miR-142-3p attenuates the invasive capacity
of p53R172H-expressing tumour cells. MiR-142-3p dysregulation is known to be associated with cancer progression,
metastasis and the miRNA is downregulated in patients with PDAC. Here we link TP53 gain-of-function mutations to
Dnmt1 expression and in turn miR-142-3p expression. Additionally, we show a correlation between expression of these
genes and patient survival, suggesting that they may have potential to be therapeutic targets.
Introduction
PDAC is the most common and most aggressive form of
pancreatic cancer and has very poor prognosis, with an
average 5-year survival of <10%1. This is often due to the
disease being diagnosed only after metastatic onset, and
its resistance to conventional therapeutics2. A better
understanding of the molecular events governing PDAC
progression is required to develop more suitable ther-
apeutic interventions.
Around 90% of sporadic human PDACs are initiated by
mutations to the K-RAS proto-oncogene, which results in
constitutive activation of K-RAS signalling3. Mouse stu-
dies with targeted mutation of Kras develop pancreatic
intraepithelial neoplasia (PanIN), which progress slowly
and lead to malignant adenocarcinomas at a low fre-
quency4. The majority of mutant Kras-induced PanINs
undergo senescence and require further mutations in
tumour suppressors, such as Trp535,6, Cdkn2a7, Tgfbr28,
Smad49 or Pten10,11, to progress into invasive
adenocarcinomas.
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Mutations in TP53 are present in ~40–70% of PDAC
patients12. The majority of these mutations occur in the
DNA-binding domain of TP53, resulting in a protein
which lacks the capacity to bind DNA13. The mutated
TP53 proteins have dominant-negative effects on tran-
scription as the insertion of just one mutated version into
the TP53 homo-tetramer prevents its function14. Addi-
tionally, a number of studies have shown that specific
mutations in TP53, such as p53R172H, impart additional
gain-of-function characteristics, including initiation of
metastasis, which are not observed following TP53 loss5,6.
Mutations to PTEN are not observed with high fre-
quency in human PDACs, though hyper-activation of
signalling pathways normally inhibited by PTEN, such as
PI3K, is observed in ~60% of cases15. However, when they
do occur, they allow cells to bypass K-RAS-induced
senescence in PanIN lesions11 and thus promote forma-
tion of PDAC. Importantly, mutations to PTEN have not
been shown to induce metastasis in PDAC11.
The incidence of the gain-of-function TP53 mutations,
including p53R172H (R175H in humans), in aggressive
tumours and their documented functional role in metas-
tasis testifies to their importance, but their full molecular
impact has not yet been elucidated6,16–18. A number of
studies have strongly implicated miRNAs and their key
biogenesis enzymes, Drosha and Dicer, as critical media-
tors of mutant TP53 activity. Mutant TP53 has been
shown to interfere with Drosha interactions with DEAD-
box protein 5 (DDX5/p68)19 and DEAD-box protein 17
(DDX17/p72/p82)20, leading to reduced processing of
specific subsets of primary miRNAs. Moreover, previous
studies have shown that decreased Dicer expression can
result in metastasis21,22 and this process may involve
members of the TP53 family23,24. Mutant TP53 has also
been shown to interact with and inhibit other members of
the TP53 family: TAp63 and TAp7325. In fact, miRNAs
which are direct transcriptional targets of TAp63, miR-
130b26 and let-7i17 have been shown to be downregulated
by mutant TP53.
Together these studies strongly suggest that miRNAs
are key mediators acting downstream of gain-of-function
TP53mutations. MiRNAs relay their activity by negatively
regulating gene expression through base pairing with
hundreds of target mRNAs thus controlling gene
expression networks and giving them the potential to
affect complex cellular mechanisms such as metastasis27.
Because of these observations, we wished to specifically
focus on the miRNAs which were regulated in mouse
models of PDAC carrying the gain-of-function mutant
p53R172H. While miRNA expression profiles of PDAC in
primary patient samples have previously been published28,
none have looked specifically at how mutant TP53 affects
miRNA expression in this disease. This is critical given
that mutant TP53 has been shown to induce metastasis,
which is the predominant cause of cancer-related mor-
bidity and mortality. Here we show that mutant p53R172H
inhibits expression of miR-142-3p, a microRNA known to
drive invasion and metastasis in PDAC29. We show that
this occurs through a DNMT1-dependent mechanism
leading to increased genomic methylation around the
miR-142-3p genomic locus. Importantly, we show that
both DNMT1 and miR-142-3p expression correlate with
patient survival, which may provide opportunities for
therapeutic intervention.
Results
Mutant p53R172H expression leads to downregulation of a
subset of miRNAs in PDAC
The aim of this study was to identify miRNAs, which
were dysregulated by the gain-of-function p53R172H
mutant in PDAC and thus potentially involved in
metastasis as opposed to loss of p53 function, which does
not cause metastasis5,6. Pdx1-Cre; LSL-KrasG12D/+; LSL-
Trp53R172H/+ (KPC) mice carry pancreas-specific mutant
KrasG12D and gain-of-function p53R172H and develop
invasive and metastatic PDAC5. Tumour tissue from these
mice (hereafter referred to as Kras p53R172H) was studied,
along with tumour tissue from Pdx1-Cre; LSL-KrasG12D/+;
LSL-Trp53flox/+ (Kras p53flox) mice and Pdx1-Cre; LSL-
KrasG12D/+; Ptenflox/+ (Kras Ptenflox) mice, both of which
develop PDACs that rarely metastasise6,11. The use of
these two controls allowed us to differentiate between
microRNAs whose expression is dependent on WT p53
and those regulated by the p53R172H gain-of-function
mutant. This is particularly important as previous studies
have suggested that mutant p53R172H gain-of-function is
responsible for metastasis5,6. As Kras p53flox cells have
lower Trp53 expression than Kras Ptenflox cells, micro-
RNAs which show no change in expression between the
controls but are significantly different in the Kras
p53R172H condition are likely to be changing due to gain of
function rather than dominant-negative activity of mutant
p53R172H. Global miRNA expression profiles were inves-
tigated using miRNA microarrays, interrogating total
RNA from mouse primary PDAC tissues.
MiRNAs were included in the study if all of the samples
within at least one of the conditions had detectable signals
for it in the microarray. Using this cutoff, a total of 307
miRNAs were detected (Fig. 1a). Statistical analysis
identified 61 miRNAs which were significantly differen-
tially expressed in the Kras p53R172H samples compared to
the Kras Ptenflox samples, and six miRNAs which were
significantly differentially expressed in the Kras p53R172H
samples compared to the Kras p53flox samples (Supple-
mental Fig. 1). A total of four miRNAs, miR-142-3p, miR-
30c-2-3p, miR-340-5p and miR-378b, were found to be
dysregulated in the Kras p53R172H tissues compared to
both the Kras p53flox and Kras Ptenflox tissues. All four
Godfrey et al. Cell Death and Disease  (2018) 9:644 Page 2 of 14
Official journal of the Cell Death Differentiation Association
Fig. 1 (See legend on next page.)
Godfrey et al. Cell Death and Disease  (2018) 9:644 Page 3 of 14
Official journal of the Cell Death Differentiation Association
were downregulated in the Kras p53R172H tissues (Fig. 1b
and Table 1). RT-qPCR validation confirmed that the
expression of miR-142-3p and miR-340-5p does not differ
between the two control conditions (Kras p53flox and Kras
Ptenflox), but both miRNAs are significantly down-
regulated in the Kras p53R172H tissues (Fig. 1c). Expression
of miR-30c-2-3p and miR-378b was found to be sig-
nificant between Kras Ptenflox and Kras p53R172H but not
between Kras Ptenflox and Kras p53R172H (Fig. 1c). This
suggests that miR-142-3p and miR-340-5p expression is
directly affected by mutant p53R172H expression.
This analysis provides information about miRNA
expression changes in the physiological context of the
primary tumour environment in mouse models. However,
tissues are inherently heterogeneous with respect to cel-
lular populations. In order to test whether the miRNAs
dysregulated in the Kras p53R172H tissues were specifically
downregulated in tumour cells, we employed primary cell
lines derived from each of the tumour models. As
expected, Kras Ptenflox cell lines do not express PTEN,
consistent with LOH during tumour progression as
described previously11, and similarly Kras p53flox cell lines
do not express p53 as the remaining wild-type allele is lost
during tumourigenesis (Fig. 2a). Thus, p53 was only
observed in Kras p53R172H lines, where the mutant protein
is insensitive to degradation (Fig. 2a). RT-qPCR of the
cells lines showed that expression of miR-142-3p follows
the profile observed in the tissue samples, with no dif-
ference between the control conditions (Kras p53flox and
Kras p53R172H) and a significant downregulation in the
mutant Kras p53R172H cells (Fig. 2b). The expression of
the other miRNAs identified in tissue samples did not
show the same pattern of changes which might indicate
that the observed differences in tissue may be due to their
heterogeneity (Fig. 2b).
Next, we used a murine Kras p53flox cell line with
ectopic expression of the analogous human mutant
TP53R175H to show that the human orthologue of this
mutation was also capable of affecting the expression of
the miRNAs of interest6. As tumours in Kras p53flox mice
undergo loss of the remaining wild-type Trp53 allele,
wild-type p53 is not expressed in these cells. This allowed
us to exclude that the observed changes in miRNA
expression are due to the dominant-negative effect of
mutant p53 on wild type. Western blot analysis confirmed
that TP53 is only present in the cell line with ectopic
expression of mutant p53R175H (Fig. 2c). Ectopic expres-
sion of mutant p53R175H led to a downregulation of miR-
142-3p, which confirmed our results for the mouse pro-
tein. No change was observed for miR-30c-2-3p and
expression of miR-340-5p and miR-378b were increased
(Fig. 2d), again indicating that the altered expression of
these miRNAs is not a reproducible hallmark of mutant
p53 expression in isolated tumour-derived cells. As there
is no wild-type p53 expressed in these cells for the mutant
p53R175H to act upon in a dominant-negative manner, this
strongly suggests that miR-142-3p is being downregulated
due to the gain-of-function activity of this mutant. In
addition, these data show that the human orthologue of
the TP53 mutant is also able to affect the expression of
miR-142-3p.
Dnmt1 is dysregulated by mutant p53R172H in PDAC
Our investigations of the PDAC models did not uncover
any global changes in mature miRNA expression, so we
focused on regulatory mechanisms pertaining to the
specific dysregulation of miR-142-3p expression. Since
DNA methylation has been found to be both upregu-
lated30–33 and downregulated34–36; in a number of cancer
types including PDAC, we reasoned that dysregulated
methylation may be responsible for the observed changes
in miR-142-3p expression. Dnmt1 mRNA expression was
investigated in the primary tumour tissue from the PDAC
models and was found to be elevated in tumours from the
Kras p53R172H tissues compared to both Kras p53flox and
Kras Ptenflox tissues (Fig. 3a). Dmnt1 mRNA (Fig. 3b) and
protein (Fig. 3c) were also found to be upregulated in the
Kras p53R172H cell line compared to both the Kras p53flox
and Kras Ptenflox cell lines.
MiR-142-3p expression can be rescued by inhibition of
methylation
As we observed an inverse correlation between miR-
142-3p and Dnmt1 expression, we asked if inhibiting
(see figure on previous page)
Fig. 1 Global profiling of microRNA expression in tissues from PDAC mouse models. a Agilent microRNA microarrays were used to investigate
global microRNA expression profiles from Kras Ptenflox (n= 4), Kras p53flox (n= 5) and Kras p53R172H (n= 5)-expressing mouse pancreatic tumour
tissues. Heat map shows the hierarchal clustering and expression levels of microRNAs for all the samples in the analysis. Statistical analysis and fold
changes presented in Table 1 were calculated using a one-way ANOVA with post hoc analysis using Tukey’s honest significance difference test (HSD)
with an FDR (Benjamini Hochberg)-adjusted p value cutoff of 0.05. A list of all statistically significantly changed microRNAs can be found in
supplemental Fig. 1. b Venn diagram demonstrating the relationship between miRNAs differentially expressed in Kras p53R172H/+ vs Kras Ptenflox and
Kras p53R172H/+ vs Kras p53flox tumours. c RT-qPCR was used to validate the microarray data using the ΔΔCT method with U6 snRNA as the reference
gene. A two-sample, two-tailed, unpaired t-test was used to compare the ΔCT values from each group. Statistical significance is represented as *p <
0.05, **p < 0.01 and ***p < 0.005
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Fig. 2 Validation of microRNA expression in primary cell lines and Kras p53flox cells with ectopic expression of mutant p53R172H. a Primary
cell lines with the same genotype as the primary tissue samples used in Fig. 1 were analysed for protein expression by western blot. b The expression
of the microRNAs identified as being dysregulated in p53R172H-expressing tissues was investigated in these cell lines using the ΔΔCT method with
U6 snRNA as the reference gene. The results represent the mean of three biological repeats; the error bars represent the maximum relative quantity.
A two-sample, two-tailed, paired t-test was used to compare the ΔCT values from each group. Statistical significance is represented as *p < 0.05 and
***p < 0.005. c Kras p53flox with ectopic expression of p53R175H and a control cell line stably expressing an empty vector were analysed by western
blot. The * represents a non-specific band of unknown origin. d Expression of the microRNAs identified as being dysregulated in the Kras p53R172H
tissues was interrogated by RT-qPCR in these cell lines using the ΔΔCT method with U6 snRNA as the reference gene. The results represent the mean
of three biological repeats with the error bars representing the maximum relative quantity. A two-sample, two-tailed, paired t-test was used to
compare the ΔCT values from each group. Statistical significance is represented as *p < 0.05
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DNA methylation had an impact on miR-142-3p expres-
sion levels. We utilised 5-aza-2-deoxycytidine (5-aza-DC),
which inhibits DNMT1, DNMT3A and DNMT3B by
being incorporated into nascent DNA, where it cross links
with DNMT protein family members, sequestering them
and reducing global methylation37. Treatment of the Kras
p53R172H cell line for 24 h with 1 μM of 5-aza-DC led to a
significant induction of miR-142-3p while having no effect
on the expression of other miRNAs investigated in this
study (Fig. 4). As 5-aza-DC is a functional inhibitor of all
members of the DNMT family38, we asked if specific
inhibition of Dnmt1 was also able to affect miR-142-3p
expression. As in the case of 5-aza-DC treatment,
expression of miR-142-3p was significantly increased fol-
lowing depletion of Dnmt1 in the Kras p53R172H cell line
(Fig. 5a, b). The other miRNAs under investigation
showed mild to no change in expression following Dnmt1
depletion, demonstrating selectivity for miR-142-3p.
The miR-142 genomic locus is hypermethylated in mutant
p53R172H-expressing primary cell lines
As direct depletion of Dnmt1 and a methylation-
inhibiting drug were both shown to induce miR-142-3p
expression, direct analysis of CpG dinucleotides in the
miR-142 genomic locus was carried out. A CpG island
which overlaps the miR-142 genomic locus was identified
using Methyl Primer Express software (Applied Biosys-
tems, Waltham, MA, USA) (Fig. 6). Bisulphite sequencing
of a 378 bp fragment of the CpG island was carried out
using DNA from both the Kras p53flox and Kras p53R172H
Fig. 3 Protein and mRNA expression of Dnmt1 in PDAC mouse models. a RT-qPCR of Dnmt1 mRNA abundance in primary mouse tissues. The
ΔΔCT method was used to calculate fold change using β-actin as the reference gene with the fold change being relative to the Kras Ptenflox samples.
The * represent non-specific bands of unknown origin. b RT-qPCR of Dnmt1 expression in primary cell lines. The ΔΔCT method was used to calculate
fold change with β-actin as the reference gene with fold change normalised to the Kras Ptenflox cell line. The result represents the mean of three
biological repeats with the error bars representing the maximum relative quantity. A two-sample, two-tailed, paired t-test was used to compare the
ΔCT values from each group. Statistical significance is represented as *p < 0.05 and ***p < 0.005. c A representative western blot showing the
expression of Dnmt1, Pten, p53 and β-actin in the primary cell lines
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cell lines and clearly showed high levels of methylation of
this region in both cell lines. Importantly, a statistically
significant increase in methylation was observed in the
fragment from the Kras p53R172H cell line (Fig. 6).
Overexpression of miR-142-3p inhibits p53R172H-driven
invasion in vitro
Given that mutant p53R172H has been shown to drive
invasion and metastasis in PDAC6, we investigated the
impact of overexpression of miR-142-3p on cell invasion.
Using reverse transwell invasion assays6, we confirmed
that Kras p53flox cells have almost no invasive ability while
Kras p53R172H cells are invasive (Fig. 7a, b). This is in line
with previously published data6. Importantly, over-
expression of miR-142-3p in the Kras p53R172H cells leads
to a significant reduction in the invasive potential of these
cells in vitro (Fig. 7a–c).
Low miR-142-3p expression and high DNMT1 expression
correlate with poor survival in human cancers
The data we present here identify a novel mechanism by
which mutant p53R172H is able to decrease expression of
miR-142-3p in a mouse model of PDAC, through genomic
hypermethylation due to increased expression of DNMT1.
Therefore, we wished to determine whether miR-142-3p
or DNMT1 expression correlates with human patient
survival.
Bioinformatic analysis using the YM500v3 database
allowed us to examine 8000 small RNA sequencing data
sets and correlate survival statistics associated with their
expression39. This revealed a strong correlation between
poor survival and low miR-142-3p expression in human
PDAC (Fig. 8a). The ProGENEV2 database40 was used to
investigate any correlation between DNMT1 expression
and patient survival in PDAC. This revealed that high
DNMT1 mRNA expression correlates with poor survival
in human PDAC patients (Fig. 8b).
Discussion
Three mouse models of PDAC were used in this study:
two in which metastasis occurs only at low-frequency
Kras p53flox and Kras Ptenflox, and Kras p53R172H, in
which metastasis occurs at high frequency. Murine pri-
mary pancreatic tumour tissues and primary cell lines, as
well as ectopic expression of human mutant p53R175H in
TP53 null cells, all showed that miR-142-3p is
Fig. 4 Expression of microRNAs following treatment with 5-aza-deoxycytidine. The Kras p53R172H/+ cell line was treated with 1 µm 5-aza-
deoxycytidine (5-aza-Dc) or an equal volume of a vehicle control (DMSO) for 24 h. The expression of the microRNAs identified as dysregulated in
p53R172H-expressing tissues was quantified by RT-qPCR with U6 snRNA as the reference gene. The result represents the average of three biological
repeats with the error bars representing the maximum relative quantity. A two-sample, two-tailed, paired t-test was used to compare the ΔCT values
from each group. Statistical significance is represented as *p < 0.05 and ***p < 0.005
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downregulated in mutant p53R172H or p53R175H-expres-
sing PDAC.
A recent study found that miR-142-3p is downregulated
in human PDAC when compared to paired adjacent
normal tissue and in pancreatic cancer cell lines, and
showed that hypoxia-inducible factor (HIF1α) is a direct
target of miR-142-3p in PDAC29. High HIF1α expression
leads to increased proliferation and invasion of tumour
cells as well as inducing expression of genes involved in
EMT, such as vimentin, VEGF and E-cadherin. Mean-
while, low expression of miR-142-3p correlated with an
increased incidence in lymphatic metastasis. These results
Fig. 5 Expression of microRNAs following depletion of Dnmt1. The Kras p53R172H cell line was treated with 20 nM DNMT1 siRNA or a control
siRNA for 48 h. a A representative western blot showing the expression of Dnmt1 and p53 following Dnmt1 depletion with β-actin as a loading
control. The * represents a non-specific band of unknown origin. b The expression of the microRNAs dysregulated in p53R172H-expressing tissues was
quantified after Dnmt1 depletion by RT-qPCR with U6 snRNA as the reference gene. The result represents the mean of three biological repeats with
error bars representing the maximum relative quantity. A two-sample, two-tailed, paired t-test was used to compare the ΔCT values from each group.
Statistical significance is represented as *p < 0.05
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taken together with our findings identify both direct and
downstream secondary targets by which miR-142-3p
functions in human patients and link its expression to
invasion and metastasis. Additionally, two recent studies
have shown that increasing miR-142-3p expression in
acute myelogenous leukaemia41 and non-small cell lung
cancer42 improves chemosensitivity by decreasing autop-
hagy due to translational repression of HMGB1. However,
the previously published data does not connect dysregu-
lation of miR-142-3p to gain-of-function mutations in
TP53 nor does it identify a mechanism by which miR-142-
3p is dysregulated. Our data clearly show that the
expression of this miRNA is indirectly inhibited by
mutant p53R172H via genomic methylation due to
increased expression of DNMT1.
Our study also found that mutant p53R172H elevates the
expression of Dnmt1 in PDAC. This is in line with pre-
vious data, which has found DNMT1 to be upregulated in
both PanIN lesions and PDACs43,44. Our data show that
Dnmt1 mRNA is upregulated in mutant p53R172H-
expressing tissues and cell lines, suggesting an increase in
transcription rate or stabilisation of the Dnmt1 transcript.
DNMT1 has been shown to be a transcriptional target of
specificity protein 1 & 3 (SP1 & 3)45. A complex formed
between SP1 and wild-type TP53 has been shown to bind
the promoter of DNMT1 and repress its transcription46.
Mutant p53 is able to inhibit this complex resulting in
upregulation of DNMT1 in lung cancer patients46. It is
possible that the same mechanism is inducing Dnmt1
transcription in this PDAC model, leading to subsequent
hypermethylation of miR-142-3p.
Previous findings of the impact of miR-142-3p on
tumour progression along with the data presented in this
study, linking mutant p53R172H and DNMT1 expression,
suggest that DNMT1may be a potential therapeutic target
in PDAC. However, demethylating drugs have been
shown to have limited clinical efficacy. 5-aza-
deoxycytidine has previously been considered in cancer
treatment but was shown to be highly toxic47, though
more recent studies using low dosage of 5-aza-
deoxycytidine have demonstrated some clinical efficacy
in haematological malignancies and myelodysplastic syn-
drome48–52. A previous study showed that treatment with
5-aza-deoxycytidine in PDAC leads to upregulation of
tumour suppressors, but also increased expression of
oncogenes which promote metastasis53, limiting its use as
a therapeutic agent. Interestingly, specifically ablating
DNMT1 promotes expression of tumour suppressor
genes but does not have the undesirable effect of pro-
moting expression of oncogenes54. A number of drugs
which directly target DNMT1 are currently in develop-
ment, though most show limited therapeutic value55. One
interesting drug is minnelide, a pro-drug of triptolide.
Triptolide has been shown to be efficacious in treatment
of PDAC through induction of miR-142-3p56. Another
study has shown that triptolide is able to negatively reg-
ulate DNMT1 transcription, leading to increased expres-
sion of methylated genes57. These findings are very much
in line with our data which show that Dnmt1 inhibition
increases miR-142-3p expression and that increasing miR-
142-3p expression reduces the invasive potential of
tumour cells. This may suggest that triptolide may be
specifically useful in treatment of mutant TP53-expres-
sing PDACs.
The data presented in this study identifies a potential
new mechanism by which mutant p53R172H is able to
affect gene expression in a gain-of-function manner,
through increased expression of DNMT1 which in turn
leads to hypermethylation of miR-142-3p and perhaps
other genes. These results open up the possibilities for
therapeutic targeting of methylation in mutant p53R172H
expressing PDACs and other tumour types.
Methods
Mouse models
All mouse models have been previously descri-
bed5,6,11,58. Experiments were performed under Home
Office licence and approved by the University of Glasgow
ethics committee. Mice on a mixed background were
maintained in conventional cages with environmental
enrichment on a light-dark cycle and given access to
standard diet and water ad libitum. Genotyping was per-
formed by Transnetyx (Cordoba, TN, USA). Mice were
Fig. 6 Bisulphite sequencing reveals increased methylation
around the miR-142 genomic locus in the Kras p53R172H cell line.
a 378 bp fragment of a CpG island which contains 18 CpGs and
overlaps the miR-142 genomic locus was amplified and investigated
using bisulphite sequencing. A schematic shows the location of the
CpG island. The lollipop plot shows the location of the CpGs with
black spots representing methylated CpGs and white spots
representing non-methylated CpGs (a). A two-tailed Mann–Whitney
U-test was used to assess for statistically significant differences
between the two bisulphite sequencing groups
Godfrey et al. Cell Death and Disease  (2018) 9:644 Page 9 of 14
Official journal of the Cell Death Differentiation Association
monitored at least three times weekly and culled when
exhibiting symptoms of PDAC (swollen abdomen, loss of
body conditioning reminiscent of cachexia, jaundice,
hunching and immobility). PDAC tissue was collected and
stored at −80 °C in RNAlater (Ambion, Foster City, CA,
USA) until RNA extraction. PDAC cell lines from these
models were isolated and grown in house as described
previously6,58.
RNA extraction
Tissues were thawed on ice in the presence of RNAlater.
Once thawed, tissues were snap frozen in liquid N2 and
pulverised in a pestle and mortar before 1 ml of TRIzol
(Thermo Fisher Scientific, Waltham, MA, USA) reagent
per 1 mg of tissue was added. Chloroform (200 μl per 1 ml
of TRIzol) was then added and the sample was centrifuged
at 12,000 × g for 15 min and the aqueous layer was
removed. Isopropanol (750 μl per 1 ml of TRIzol) was
then added and the sample was precipitated overnight at
−20 °C. RNA was resuspended in ddH2O and an equal
volume of acid phenol/chloroform (50:50) was added. The
sample was centrifuged at 12,000 × g and the aqueous
layer was removed before sodium acetate (10% of final
volume) and ethanol (250% of final volume) was added
and the sample was precipitated at −20 overnight. Sam-
ples were resuspended in a suitable volume of ddH2O and
Fig. 7 miR-142-3p overexpression inhibits mutant p53-driven invasion in vitro. a Representative Z-stack images from reverse transwell invasion
assays. Kras p53flox (n= 2), Kras p53R172H+ empty vector (n= 4) and Kras p53R172H+miR-142 expression vector (n= 4) mouse primary PDAC cells
were analysed for their invasive potential. Cells were considered invasive if they migrated further than 60 μm. b Quantification of invasion by
measuring the fluorescence of cells past 60 μm relative to the total fluorescence of each stack. Each experimental repeat consisted of two transwells
each with three Z-stacks per transwell. The percentage invasion is reported relative to the Kras p53R172H cells transfected with an empty vector. Error
bars represent the pooled standard deviation for each condition. A two-sample, two-tailed, paired t-test was used to compare the average
percentage of invasion between biological repeats (n= 4) for Kras p53R172H+ empty vector and Kras p53R172H+miR-142-3p expression vector.
Statistical significance is represented as *p < 0.05. c The average change in miR-142-3p expression in cells transfected with the miR-142-3p expression
vector compared to cells transfected with empty vector. Error bars represent the standard deviation
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were quantified using a nanodrop spectrophotometer
(Thermo Fisher Scientific).
MiRNA microarrays
Agilent miRNA microarrays were carried out as per the
manufacturer’s instruction using the Agilent miRNA
microarray labelling kit (Agilent, Santa Clara, CA, USA).
In brief, 100 ng of total RNA from each PDAC tumour
tissues was dephosphorylated and labelled with Cy3-pCp
using T4 RNA ligase. The labelled RNA for each sample
was then applied to one of the eight miRNA microarrays
on each slide and sealed with a gasket cover, before being
Fig. 8 Low miR-142-3p and high DNMT1 correlate with a poor prognosis in human PDAC. a The data set in the YM500v3 database shows a
clear correlation between low miR-142-3p expression and poor survival in human PDAC. b The ProGENEV2 database was interrogated for correlations
between DNMT1 expression and human PDAC patient survival. All data sets which show a statistically significant correlation are reported, all of which
show a correlation between high DNMT1 expression and poor patient survival
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placed in a hybridisation oven at 55 °C for 20 h while
rotating at 20 rpm. The labelled microarrays were scanned
using the Agilent G2565CA microarray scanner and the
features were defined and extracted using Agilent feature
extraction software (version 11.0) using default settings.
All fold change and statistical analysis was carried out
using Genespring (Agilent). All non-mouse miRNAs were
removed from the analysis along with any miRNA, which
was not detected in all samples from at least one condi-
tion. Statistical analysis was carried out using a one-way
ANOVA with a false discover rate (FDR) p value of 0.05
and post hoc analysis using Tukey’s honest significant
difference test (HSD).
Taqman RT-qPCR
RT-qPCR of miRNAs was carried out using Taqman
miRNA assays (Applied Biosystems) as per the manu-
facturer’s instruction. In brief, 100 ng of total RNA was
reverse transcribed using the TaqMan miRNA reverse
transcription kit (Applied Biosystems). RT-qPCR was
achieved using the Applied Biosystems 7500 RT-qPCR
thermocycler under default conditions. The following
Taqman assays were used in this study: U6 – 001973,
miR-142-3p – 000464, miR-30c-2-3p – 002110, miR-340-
5p – 002258 and miR-378b – 465314_mat.
SYBR green RT-qPCR
Reverse transcription for RT-qPCR of mRNAs was
achieved using Superscript 3 (Invitrogen) reverse tran-
scriptase and random primers as per the manufacturer’s
instruction. Aliquot of 100 ng of total RNA was used for
each reaction. The following primers were used in this
study: Dnmt1 forward – GTGCTCTCACCCAGAGCCCC,
Dnmt1 reverse – GGGTGCTTGACAGAAGCGCT, β-
actin forward – GTGGACAGTGAGGCCAGGAT, β-
actin reverse – GATTACTGCTCTGGCTCCTAGCA.
Bisulphite sequencing
DNA was extracted from Kras p53flox and Kras p53R172H
cell lines using the DNeasy blood and tissue kit (Qiagen,
Venlo, the Netherlands) as per the manufacturer’s
instruction. DNA was treated with sodium bisulphite
using the EpiTect plus DNA bisulphite kit (Qiagen) as per
the manufacture’s instruction. Following bisulphite con-
version, DNA was washed and eluted from a MinElute
DNA spin column. Methyl primer Express software
(Applied Biosystems) was used to interrogate a sequence
of DNA 700 bp both up and downstream of the miR-142
precursor sequence. Using the definition of a CpG island
as a sequence with a CpG observed/expected ratio >0.6, a
590 bp CpG island was observed overlapping the miR-
142-3p precursor sequence. Primers were designed to
amplify a 378 bp fragment of the CpG island which con-
tained 18 CpG dinucleotides.
PCR was carried out using EpiMark Hot Start Taq DNA
Polymerase (NEB) using the following primers: forward –
TGGATGAGTGTATTGTGGGT and reverse – AACC
CCAATAACAAAATCAAAC as per the manufacturer’s
instruction. The resulting fragment was size excluded on
an agarose gel and extracted, before being ligated into
pGEM-T Easy (Promega, Madison, WI, USA). The
resulting ligation was transformed into DH5α competent
cells and selected using blue white screening. A total of
ten white colonies were selected and amplified for each
Kras p53flox and Kras p53R172H cell line. DNA from the
amplified colonies was prepared using Wizard Plus SV
Miniprep kit (Promega) and Sanger sequenced using T7
and SP6 primers. A consensus sequence was then created
using SeqTrace59. Consensus sequences were edited to
remove and sequence corresponding to the pGEM-T Easy
backbone using BioEdit60. The sequences were then
compared to the genomic sequence of the CpG island
using BiQ Analyzer61. Samples were accepted as indivi-
dual if they had at least one non-CpG cytosine residue
independent of the other samples. Samples were only
accepted if they had a conversion efficiency of >95%
judged by abundance of non-CpG cytosine residues.
SDS-PAGE and western blotting
Cells were lysed in radioimmunoprecipitation assay buffer
(RIPA) (50mM Tris, 150mMNaCl, 0.1% SDS, 0.5% sodium
deoxycholate, 1% NP-40) supplemented with Complete
Protease Inhibitor Cocktail Tablets (Roche, Basel, Switzer-
land) immediately prior to use. The antibodies used in this
study were: β-actin (Sigma, 20-33), PTEN (Cell Signalling,
9552), p53 (Abcam, ab240) and DNMT1 (Cell Signalling,
D63A6). Images were revealed using the LI-COR infra-red
imager using LI-COR infra-red secondary antibodies.
Cell culture
All cell lines were grown in DMEM (Gibco, Waltham,
MA, USA) supplemented with 10% Foetal bovine serum
(FBS), L-glutamine (20 mM) and penicillin/streptomycin
(50 ug/ml). The TP53 null cell lines with stable ectopic
expression of mutant p53R175H were additionally supple-
mented with G418 (400 μg/ml). All cell lines were grown
in a humidified cell culture incubator with 20% O2 and 5%
CO2 at 37 °C.
siRNA transfection
All siRNA transfections were achieved using Dharma-
fect 1 transfection reagent as directed by the manu-
facturer’s instruction. Both DNMT1 (4390771) and
control (4390844) siRNAs were purchased from the
Silencer Select range of validated siRNAs (Thermo Fisher
Scientific). A final concentration of 20 nM siRNA was
used for all siRNA transfections. Both RNA and protein
lysate were collected 48 h post transfection.
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5-aza-Deoxycitidine treatment
Cells were treated with 1 nM 5-aza-deoxycitidine or an
equivalent volume of vehicle (DMSO) for 48 h before
being collected for analysis.
Reverse Invasion assays
60 μl of Matrigel was placed into cell culture transwell
inserts and incubated at 37 °C with 5% CO2 for 1 h in 12
well plates. The inserts were inverted and 100 μl of a
350,000 cells/ml suspension was applied to the mem-
brane. Plates were incubated at 37 °C with 5% CO2,
inverted, for 5 h to allow adherence. The plates were then
reverted and the inserts were washed twice in serum free
DMEM, before being placed into fresh wells containing 1
ml of serum free media. 100 μl of media with 10% serum
and 10 ng/ml Hepatocyte Growth Factor (HGF) was then
placed into the transwell and the cells were incubated at
37 °C and 5% CO2 for 48 h. Cells were stained in 4 nM
Calciene for 1 h before being imaged using a confocal
microscope.
Non-invasive cells were removed from the base of the
membrane, before the transwell was placed onto a large
coverslip on the stage of a confocal microscope. Z-stacks
were taken from the inner surface of the membrane at
intervals of 15 μm with a total of 15 images being taken.
The same positions were used for each transwell in order
to reduce user bias. Each experimental repeat consisted of
2 transwells per condition with 3 Z-stacks being taken per
transwell.
Fluorescence for each image of a stack was quantified
using ImageJ. A fluorescent signal of cells past 60 μm was
considered invasive. The percentage of fluorescent signal
past 60 μm was calculated as a percentage of the total
fluorescent signal for each stack, and an average percen-
tage of invasion was calculated for each transwell. Sta-
tistical analysis was carried out using a two-sample, two-
tailed, paired t-test, comparing the average invasion of
each transwell in a condition (n= 4). Conditions with
overexpression of miR-142-3p included a preceding day,
where cells were transfected with either an empty vector
or one containing the miR-142 primary microRNA
sequence. Transfected cells not used for the invasion
assay were used to quantify the degree of miR-142-3p
overexpression using Taqman assays.
Analysis of human patient survival
The YM500v3 database was interrogated to see how
miR-142-3p expression correlated with human patient
survival. A single PDAC data set was used for the analysis.
The ProGENEV2 database was used to investigate the
effect of DNMT1 expression on human patient survival.
Of the six PDAC data sets available, three (GSE28735,
GSE50827 and GSE71729) had a p value of <0.1 and all
correlations found that high DNMT1 mRNA expression
correlates with poor survival.
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